1. A composition comprising ex vivo expanded cells that selectively damage tumor-associated vasculature compared to normal vasculature

2. The composition of claim 1 wherein the selectivity is 2-fold.

3. The composition of claim 1 wherein the selectivity is at least 5-fold.

4. The composition of claim 1 wherein the selectivity is at least 100-fold.

5. The composition of claim 1 wherein at least 2% of the ex vivo expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

6. The composition of claim 5 wherein at least 5% of the ex vivo expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

7. The composition of claim 6 wherein at least 10% of the ex vivo expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

8. The composition of claim 6 wherein at least 50% of the ex vivo expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

9. The composition of claim 1 wherein the ex vivo expanded cells are T cells.

10. The composition of claim 1 wherein the ex vivo expanded cells are NK cells.

11. The composition of claim 1 wherein the ex vivo expanded cells are CIK cells.

12. The composition of claim 1 wherein the ex vivo expanded cells recognize an antigen present on tumor vasculature that is not present in normal vasculature.

13. The composition of claim 1 wherein the ex vivo expanded cells recognize an antigen expressed during neoangiogenesis

14. The composition of claim 12 or 13 wherein the antigen recognition is non-classical MHC restricted.

15. The composition of claim 12 or 13 wherein the antigen recognition is MHC-independent.

16. The composition of claim 1 wherein the ex vivo expanded cells express a cell-surface receptor which recognizes heat shock protein 47.

17. The composition of claim 1 wherein the ex vivo expanded cells express a cell-surface receptor which recognizes HLA.

18. The composition of claim 1 wherein the ex vivo expanded cells express a cell-surface receptor which recognizes IL-12 receptor or a part thereof.

19. The composition of claim 1 wherein the ex vivo expanded cells express a cell-surface receptor which recognizes a heat shock protein.

20. The composition of claim 1 wherein the ex vivo expanded cells comprise cells expressing both CD3 and CD56.

21. The composition of claim 1 wherein the ex vivo expanded cells comprise cells that kill tumor cells.

22. The composition of claim 1 further comprising a chemotherapeutic compound.

23. The composition of claim 1 further comprising an agent which links the ex vivo expanded cells to a selected compound.

24. The composition of claim 1 wherein the agent binds to the ex vivo expanded cell non-covalently.

25. The composition of claim 24 wherein the agent is a bi-specific antibody.

26. The composition of claim 24 wherein the agent comprises at least two covalently bound antibodies.

27. The composition of claim 25 wherein the bi-specific antibody binds to the selected compound.

28. The composition of claim 24 wherein the agent comprises an antibody which binds to the ex vivo expanded cells.

29. The composition of claim 28 wherein the selected compound is covalently bound to the antibody.

30. The composition of claim 28 wherein the selected compound is non-covalently bound to the antibody.

31. The composition of claim 23 wherein the selected compound is selected from the group consisting of: a toxin, an antibody, a detectably labeled molecule, an immuno-modulator, and a radioactive compound.

32. The composition of claim 1 further comprising an immuno-modulator.

33. The composition of claim 1 further comprising a chemotherapeutic compound.

34. A method for treating a patient suffering from a cancer, the method comprising administering to a patient the composition of any of claims 1, wherein the ex vivo expanded cells are autologous to the patient.

35. The method of claim 34 wherein the cancer stimulates neo-angiogenesis.

36. The method of claim 34 wherein the tumor is a solid tumor.

37. The method of claim 34 wherein the ex vivo cells are capable of undergoing replication in culture.

38. The method of claim 34 wherein the composition is administered without co-administration of a cytokine.

39. The method of claim 34 wherein the composition is not administered within five days of the administration of a cytokine.

40. The method of claim 34 wherein at least 10^5 of the ex vivo expanded cells are administer in a given day.

41. The method of claim 34 where the composition is administered at least two times within 7 days.

42. The method of claim 34 where the composition is administered at least two times within 30 days.

43. The method of claim 34 wherein the patient is suffering from a cancer selected from a stage 1 cancer, stage 2 cancer, stage 3 caner, or a stage 4 cancer.

44. The method of claim 34 wherein the patient is suffering from a cancer selected from a low grade cancer, an intermediate grade cancer, and a high grade cancer.

45. A method for preparing a composition comprising ex vivo expanded cells that selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues, the method comprising:

a) providing a composition comprising NK cells; and

b) enriching the composition for cells that express a receptor for heat shock protein 47.

46. A method for preparing a composition comprising ex vivo expanded cells that selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues, the method comprising:

a) providing a composition comprising NK cells; and

b) enriching the composition for cells that express a receptor for HLA.

47. A method for preparing a composition comprising ex vivo expanded cells that selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues, the method comprising:

a) providing a composition comprising NK cells; and

b) enriching the composition for cells that express a receptor for interleukin-12.

48. A method for ex vivo expansion of EAT cells comprising culturing pre-cursor in agitated medium.

49. The method of claim 48 wherein the cells are grown in a membrane enclosure.

50. The method of claim 48 wherein the cells are grown in bioreactor.

51 ~~49~~. The method of claim ~~46~~ 48 wherein the cells a shipped to location other than the site of expansion.

52 ~~50~~. The method of claim 34 wherein treatment comprises outpatient treatment.

53 ~~51~~. The method of claim 34 wherein the patient is suffering from a non-malignant disease.

Rule 1.126

54 ~~52~~. The method of claim 34 wherein the patient is a cancer survivor.

55 ~~53~~. The method of claim 34 wherein the patient is healthy.

56 ~~54~~. The method of claim 34 wherein the patient is at increased risk for cancer.

57 ~~55~~. A method for treating a patient comprising administering to a patient the composition of any of claims 1, wherein the ex vivo expanded cells are allogenic to the patient.

58 ~~56~~. The method of claim ~~55~~ 57 wherein the cells are immortalized.

59 ~~57~~. The composition of claim 1 wherein the ex vivo expanded cells harbor a stable transgene comprising a regulable suicide gene.